Shibani Pati, MD, PhD
Research and Clinical Interests
I am a vascular biologist with an interest in the role of endothelial dysfunction and vascular compromise in the pathogenesis of human disease. My specific areas of investigation involve the use of stem cells and novel resuscitative modalities that can mitigate endothelial dysfunction in traumatic injury. Abnormalities in vascular permeability leading to inflammation, tissue edema, and end-organ dysfunction significantly contribute to the morbidity and mortality associated with a number of human disease processes. For example, although a number of factors contribute to the high mortality and morbidity associated with traumatic brain injury (TBI), the development of cerebral edema with brain swelling remains one of the most significant predictors of outcome. Similarly both hemorrhagic shock and septic shock are characterized by abnormal vascular permeability, which contributes to the development of shock-associated acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Despite the clear importance of abnormal vascular permeability in a number of human disease processes, there exists no therapeutic modality in current use to attenuate it. My lab is currently funded by the NIH and the Department of Defense (DOD).
Cellular Therapy and Cell Production Lab
We have embarked on an endeavor to produce clinical grade Mesenchymal stem cells (MSCs) in partnership with our parent organization Blood Systems Inc. in Tempe, Arizona. The lab at BSRI is the scientific core of the program and the clinical production core is in Tempe, AZ. The goal of this program is to produce cellular therapeutics for clinical trials and long term commercialization.
CIRM-BSRI Conference on Cellular Therapies in Trauma and Critical Care Medicine
We have now organized and hosted two meetings that have been focused upon cellular therapies in trauma and critical care. The first was held in 2012 and the most recent meeting was held in September, 2015. The website for the meeting is www.cttacc.org. The goal of this meeting is to bring together the expertise and input of blood bankers, clinicians running trials, basic scientists, companies, FDA, NIH, AABB, and the DOD representatives to discuss existing barriers in the translation of cell therapies in trauma and critical care medicine, a field with few therapeutic options. The areas covered spanned translationally relevant topics such as cell sourcing, cell expansion, cell storage, safety, funding, pre-clinical studies and clinical trials. Our speakers had diverse expertise and knowledge in these areas. Our target audience included clinicians, physician- scientists, and basic scientists who are currently working in or anticipate working in the field of cellular therapeutics in critically ill patients. The next meeting is scheduled for May 17-19, 2017 in San Francisco at the Marines Memorial Club. For registration please go to www.cttacc.org.
- Menge T, Zhao Y, Zhao J, Wataha, K, Gerber M, Zhang J, Letourneau P, Redell J, Shen L, Wang J, Peng Z, Xue H, Kozar R, Cox CS Jr, Khakoo AY, Holcomb JB, Dash PK, Pati S. Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury. Sci Transl Med;4: 161ra50.
- P Letourneau, T Menge, K Wataha, C Wade, CS Cox Jr, JB Holcomb, S Pati. Human bone marrow derived mesenchymal stem cells regulate leukocyte-endothelial interactions and activation of transcription factor NF-kappa B. Journal of Tissue Sci and Engineering. S3:001.
- Pati S, Gerber MH, Menge TD, Wataha KA, Zhao Y, Baumgartner JA, Zhao J, Letourneau PA, Huby MP, Baer LA, Salsbury JR, Kozar RA, Wade CE, Walker PA, Dash PK, Cox CS Jr, Doursout MF, Holcomb JB. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One. 2011;6(9):e25171. Epub 2011 Sep 28 PMID: 21980392
- Pati S*., Rogers, T, Khakoo, AY, Lederer, J. Mesenchymal Stem Cells Stimulate Protective Genetic Programming of Injured Cardiac Ventricular Myocytes. Journal of Mol. And Cell. Cardiology 2010
- * Indicates Co-first author
- Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber M, Harting MT, Redell JB, Grill RJ, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK. Human mesenchymal stem cells inhibit vascular permeability by modulating VE-cadherin/beta-catenin signaling. Stem Cells Dev. 2010 May 6. [Epub ahead of print] PMID: 20446815
- Pati S, Matijevic N, Doursout MF, Ko T, Cao Y, Deng X, Kozar RA, Hartwell E, Conyers J, Holcomb JB. Protective effects of fresh frozen plasma on vascular endothelial permeability, coagulation, and resuscitation after hemorrhagic shock are time dependent and diminish between days 0 and 5 after thaw. J of Trauma. 2010 Jul;69 Suppl 1:S55-63. PMID: 20622621
- Pati S.*, Khakoo AY., Anderson SA., Reid W., Elshal MF., Rovira II, Nguyen AT., Malide D., Combs CA., Hall G., Zhang J., Raffeld M., Rogers TB., Stetler-Stevenson W., Franks JA., Reitz M., Finkel T. Human Mesenchymal Stem Cells exert potent antitumorigenic effects in a model of Kaposi's Sarcoma. J. Exp. Med. 2006 May 15;203(5):1235-47. *Indicates Co-first author
- 2006- 2008 Vivian L. Smith Postdoctoral Fellow Award in Neurocognitive Disorders Baylor College of Medicine and University of Texas, Houston, TX
- 2007-2009 NIH LRP Award for Pediatric Research in TBI
- 2009-2011 NIH LRP Award for Pediatric Research in Stem Cells and Injury
- 2009-2011 Mission Connect Award (TIRR Foundation) for research in High Throughput Screening of Drugs for Motor Neuron Stem Cell Differentiation and Survival
- 2010 Mission Connect (TIRR Foundation Award) for the study of the Immunomodulatory effects of MAPCs in TBI
- 2011 Scott Murphy Guest Lectureship BEST/AABB San Diego
- Associate Professor, Scientific Director of Cellular Therapies Blood Systems Inc.
- Laboratory Medicine
- Stem cell therapeutics in trauma and critical care medicine
- Control of vascular leak in disease and mitigating endothelial damage
- Novel Resuscitative Modalities- plasma (FFP), platelets, Lyophilized plasma, pathogen reduced plasma, factor concentrate
- Storage Lesion of FFP and Platelets
- See UCSF Directory
- Blood Systems Research Institute
- 270 Masonic Avenue
- San Francisco, CA 94118
Other UCSF Organizational Association(s)
- Blood Systems Research Institute